Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Axsome Therapeutics (AXSM) reported a Q4 loss of $0.96 per share, which was better than the Zacks Consensus Estimate of a $1 loss. This is an increase in loss compared to $0.73 per share a year ago.
February 18, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics reported a Q4 loss of $0.96 per share, better than the expected $1 loss, but worse than last year's $0.73 loss.
The better-than-expected earnings per share loss suggests a positive short-term impact on the stock price, as it indicates the company is performing better than analyst expectations. However, the increase in loss compared to last year may temper some of the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100